Literature DB >> 6692037

Refractory dysmyelopoietic anemia and acute leukemia.

D S Rosenthal, W C Moloney.   

Abstract

One hundred and seventeen consecutive patients with refractory dysmyelopoietic anemia (RDA) were followed and studied over 6 yr. All RDA cases had at least two marrow cell lines involved with dysplasia and usually all three. Morphologically, the series could be divided into 55 cases that had primarily "erythroid" hyperplasia and 62 cases with primarily "myeloid" dysplasia. There was a significantly higher number of acute leukemias in the myeloid group, 21/62 (33.9%), than in the erythroid group, 7/55 (12.7%). Of the 117 cases, 64 had marrow culture studies performed using implanted diffusion chambers (DC) in an irradiated rat host. There was a highly statistically significant correlation between the development of leukemia and abnormal growth in DC during the RDA stage.

Entities:  

Mesh:

Year:  1984        PMID: 6692037

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Refractory myelodysplastic anaemias with hypocellular bone marrow.

Authors:  Y Yoshida; S Oguma; H Uchino; T Maekawa
Journal:  J Clin Pathol       Date:  1988-07       Impact factor: 3.411

2.  Refractory anaemia terminating in a combined lymphoproliferative and myeloproliferative disorder.

Authors:  L Camba; M V Joyner
Journal:  J Clin Pathol       Date:  1985-03       Impact factor: 3.411

3.  Erythrocyte ferritin concentration in patients with myelodysplastic syndromes.

Authors:  S W Peters; S J May; A Jacobs
Journal:  J Clin Pathol       Date:  1985-01       Impact factor: 3.411

4.  Amsacrine, cytarabine and etoposide in the treatment of bad prognosis acute myeloid leukemia.

Authors:  A Wahlin
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

5.  Refractory cytopenias: clinical course according to bone marrow cytology and cellularity.

Authors:  A Riccardi; M Giordano; M Girino; M Cazzola; C M Montecucco; E Cassano; M Danova; G Ucci; A Castello; A Coci
Journal:  Blut       Date:  1987-03

6.  Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group.

Authors:  H H Gerhartz; R Marcus; A Delmer; H Zwierzina; T de Witte; A Jacobs; G Visiani; D Fiere; P Sonneveld; B Labar
Journal:  Infection       Date:  1992       Impact factor: 3.553

Review 7.  Myelodysplastic syndromes: pathogenesis, functional abnormalities, and clinical implications.

Authors:  A Jacobs
Journal:  J Clin Pathol       Date:  1985-11       Impact factor: 3.411

8.  Primary myelodysplastic syndrome with complex chromosomal rearrangements in a patient with Klinefelter's syndrome.

Authors:  S M Abidi; M Griffiths; D G Oscier; G J Mufti; T J Hamblin
Journal:  J Med Genet       Date:  1986-04       Impact factor: 6.318

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.